Next Generation Diabetes Therapy Drug Delivery Market
Report ID: SQMIG35I2471
Report ID: SQMIG35I2471
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35I2471 |
Region:
Global |
Published Date: January, 2026
Pages:
184
|Tables:
87
|Figures:
71
Global Next Generation Diabetes Therapy Drug Delivery Market size was valued at USD 39.31 Billion in 2024 and is poised to grow from USD 42.58 Billion in 2025 to USD 80.57 Billion by 2033, growing at a CAGR of 8.3% during the forecast period (2026–2033).
The global next generation diabetes therapy and drug delivery market growth is driven by the relentless increase in global diabetes prevalence. There is a large unmet need for more effective, convenient, and less invasive treatments. The market is moving beyond simple glucose control towards therapies that will facilitate weight loss, provide cardiovascular benefits and increase overall quality of life. This movement is causing increased R&D and market expansion.
However, the global next generation diabetes therapy and drug delivery market analysis highlights the barriers facing future growth in the market. The costs for these new therapies and devices are extreme, resulting in significant reimbursement and access issues. The regulatory pathway to approval for these products is long and costly. The market is also currently faced with the technical challenge of whether they can develop truly non-invasive or reliable "closed loop" systems which is necessary to completely automate all aspects of managing diabetes care.
How Are AI and Connectivity Shaping the Global Next Generation Diabetes Therapy Drug Delivery Market?
The Global Next Generation Diabetes Therapy and Drug Delivery Market trends are largely influenced by artificial intelligence (AI) and wireless technology. Devices such as smart insulin pens, continuous glucose monitors (CGMs), insulin pumps, etc. are now capable of connecting to various mobile apps. AI algorithms utilize this data and develop insights providing patients and their clinicians personalized recommendations for dosing and insight into hypoglycemic events. Thus, allowing patients to utilize a connected diabetes ecosystem.
In early 2025, an early-stage device manufacturer, Tandem Diabetes Care, received expanded FDA approval for its Control-IQ technology that has an updated algorithm that utilizes real time CGM data to both adjustable basal insulin and provide automatic correction boluses, advancing the automation of insulin delivery and minimizing the user burden of diabetes management.
Market snapshot - 2026-2033
Global Market Size
USD 35.78 Billion
Largest Segment
Continuous Glucose Monitors
Fastest Growth
Automated Insulin Delivery (AID) / Closed-Loop
Growth Rate
7.69% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Next Generation Diabetes Therapy Drug Delivery Market is segmented by Product, Demographic, Indication, End User and region. Based on Product, the market is segmented into Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas. Based on Demographic, the market is segmented into Adult Population (>14years) and Child Population (14years). Based on Indication, the market is segmented into Type 1 Diabetes and Type 2 Diabetes. Based on End User, the market is segmented into Diagnostic/Clinics, ICUs and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The Continuous Glucose Monitors (CGM) segment holds the largest share of the global next generation diabetes therapy and drug delivery market share. CGM's share is primarily due to their foundational role in diabetes management AND one having a growing role in Type 2 diabetes management. CGM's real-time data is critical for making treatment choices. CGM's are the requisite device for advanced systems like AID; with increasing reimbursement coverage, they have become the leading device in the market.
The Automated Insulin Delivery (AID) / Closed-Loop Systems category is fastest growing in the global next generation diabetes therapy and drug delivery market. The rapid growth is powered by the incredible demand from patients to automate diabetes management and lessen the burden of the disease daily.
The global next generation diabetes therapy and drug delivery market size is quite affected by the Type 1 Diabetes patient group. The reason for this is due to the fact that Type 1 diabetes patients absolutely require intensive insulin therapy. Therefore, they are the only patients which would have multiple injections of insulin on a day-to-day basis or continuous infusion. Thus, Type 1 patients are the main users of insulin pumps, continuous glucose monitors (CGM), and Advanced Insulin Delivery (AID) systems. These technologies are mandatory for having tight glycemic control and avoiding complications.
The Type 2 Diabetes segment is the fastest growing segment in the global next generation diabetes therapy and drug delivery market. This is primarily due to increased indications for CGM in the much larger Type 2 patient population, especially those on intensive insulin therapy.
To get detailed segments analysis, Request a Free Sample Report
North America occupies the most significant position in the global next generation diabetes therapy and drug delivery regional outlook due to a high prevalence of diabetes and high healthcare expenditures as well as favourable reimbursements for advanced diabetes therapies such as CGM and insulin pumps. The North American region has a high rate of patient awareness of new medical devices and an increased, rapid uptake of devices and delivery technologies as they are available. There are also a number of major market players who are based in North America.
The United States holds the largest share of the North American next generation diabetes therapy and drug delivery market with a competitive share. This is a great market due primarily to its very large, well insured patient populations. The patient advocacy groups also carry a lot of clout. The clear regulatory pathways are an important driver for the presence of technology. Recent developments depict a marked push toward interoperability, enabling multiple pumps and CGMs to communicate and function in combination with one another.
Canada shows progress due to some significant movement in the North American next generation diabetes therapy and drug delivery market. Also, with new provincial reimbursement programs for diabetes technologies, Canada will move quickly to bring CGM devices and insulin pumps to their citizens due to the strong focus on improving access. Recently, provinces in Canada made significant moves by including CGM systems into their public drug and device benefit programs and expanding reimbursement for a given period of time, which is expected to improve uptake in the spring of 2024.
The European region serves as an essential element of the global next generation diabetes therapy and drug delivery regional forecast due to its strong national healthcare systems which are seeking to dismiss long-term future costs by investing in technologies designed to avoid termed expensive complications of diabetes. The European region remains an example of where strong clinical evidence is maintained. A higher standard of care is realistic and representative of the EU value system.
Germany is the strongest market for the European region next generation diabetes therapy and drug delivery market due to its size and the reimbursement system surrounding medical devices. The strongest area is one which has structured and mandated disease management programs for each, such as the bulk adoption of 'Flash Glucose Monitoring' cost-efficiently replacing traditional CGM.
The UK is growing the fastest in the European region next generation diabetes therapy and drug delivery market, largely due to the latest guidance provided by the National Institute for Health and Care Excellence (NICE) recommending CGM for all persons living with Type 1 diabetes. The consistency of population outcomes also appears to be a driver for recent standards in care.
France is seeing a steady growth in the European next generation diabetes therapy and drug delivery market. This growth continues to be driven in part by its focus on technological development and its sufficiently mature system for evaluating and reimbursing new medical technologies. Its focus on quality of life, and particularly areas related to people living with diabetes, continues to be an underlying consideration. Recently we have seen the rapid adoption of patch pumps due to their inconspicuousness and ease of use.
The Asia Pacific region is expected to be the fastest growing region in the global next generation diabetes therapy and drug delivery market revenue, due to huge spikes in diabetes diagnosis and treatment occurring in China and India, increasing disposable incomes, and their changes in healthcare infrastructure. As patients become more aware and have access to available technology, the market is poised for explosive growth off of a lower base.
Japan is a major player market in the Asia Pacific region next generation diabetes therapy and drug delivery market, due to its aging population and high standard of medical care. Its focus on miniaturization and user design is very important. Recent developments include all Japanese companies developing ultra-thin, flexible CGM sensors.
South Korea is growing rapidly in the Asia Pacific next generation diabetes therapy and drug delivery market, mainly due to its tech-savvy population and government assistance toward building the biotech industry. Its focus on digital health is very important. Recent changes include the launch of several diabetes management apps linked with the local CGM and blood glucose meter brands.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Diabetes Prevalence
Technological Advancements and Patient Demand
High Cost and Reimbursement Hurdles
Interoperability and Data Security
Request Free Customization of this report to help us to meet your business objectives.
The global next generation diabetes therapy and drug delivery industry trends show a market dominated by specialized medical device and pharmaceutical companies. In drug delivery, major players include Medtronic, Insulet, and Tandem for insulin delivery and Abbott and Dexcom for Continuous Glucose Monitoring (CGM). For drug delivery, Eli Lilly and Novo Nordisk are the leaders. The strategy these competitors are taking is based on patent portfolios, R&D investment, clinical research studies, and established relationships with endocrinologists and payers.
As the competitive landscape evolves, startup companies are beginning to disrupt the diabetes therapy and drug device markets by focusing efforts on enhancing user-based experiences and developing data driven solutions. These startups are providing solutions based on novel delivery mechanisms (for example the new class of smart patch drug delivery systems), more convenient CGM sensors, or artificial intelligence powered software platforms. The strategy of these startups is focused on identifying and addressing particular pain points in the user experience—device size, ease of use, and decision support elements that larger firms missed.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global next-generation diabetes management and drug delivery market is an evolving and fast-paced area of health care primarily directed by two key influencing factors: global diabetes epidemic is worsening and this sector is experiencing unprecedented technological progress. The core market drivers are now focused on the path towards full automation of diabetes management, known as the artificial pancreas. The future of the sector will involve more connectivity, increased algorithms, and less invasive devices, all aimed at decreasing the overall burden of daily management for patients with a chronic condition.
Regional markets, particularly in North America, demonstrate strong growth reflecting strong spending on healthcare and the early adoption of new technologies by patients. In order to support the expansion of these technologies, the industry faces the challenge of high costs and often limited reimbursement opportunities. However, the clear clinical benefits of these technologies will continue to advance the market forward. The CGM market is the largest, but as integrated AID systems are the fastest growth category and the direction of diabetes care, it represents the future.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 39.31 Billion |
| Market size value in 2033 | USD 80.57 Billion |
| Growth Rate | 8.3% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Next Generation Diabetes Therapy Drug Delivery Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Next Generation Diabetes Therapy Drug Delivery Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Next Generation Diabetes Therapy Drug Delivery Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Next Generation Diabetes Therapy Drug Delivery Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
